Beijing hospital-drug maker focused on injectable proton-pump inhibitors and oncology injectables sold mainly to Chinese hospitals.
Beijing hospital-drug maker focused on injectable proton-pump inhibitors and oncology injectables sold mainly to Chinese hospitals.
Sells hospital injectables, led by acid-reducing injections, to public hospitals through distributors, with prices set by national volume-based procurement rounds that reward the lowest bidder. Earnings therefore depend on winning rounds rather than on brand loyalty.
In one line: A small, injectables-only Hospira.
Moat: none (distribution). Commodity hospital generics with little pricing power under national procurement tenders.
Headquarters: Beijing, China · Employees: 799
Size Beijing Aosaikang Pharmaceutical (002755.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.60B, the 1433rd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥11.53 on 18 Nov 2026.
Performance Over six months the shares fell 31.3%, against -7.7% for the median peer and -20.0% for the China market (cap-weighted) — 4th lowest of 20 in its peer set.
Growth Revenue fell 12.8% over the last twelve months (peer median +6.8%); the operating margin is 12.0% (peer median 12.4%).
Valuation It trades at 57.4× forward earnings against a peer median of 23.8× (most expensive of 15).
Price implies For today's price to make sense, revenue must grow about 13% a year for seven years (Req g). Recent delivered growth is -14%, so the hurdle is +27 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 15.2 points above its cost of capital (6.1% WACC).
Next results Next results expected around 26 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.59B | CN¥1.76B | CN¥1.76B | CN¥1.43B | CN¥1.85B |
| Revenue growth | — | 0% | +23% | -23% | — |
| Gross profit | CN¥1.38B | CN¥1.38B | CN¥1.40B | CN¥1.12B | CN¥1.56B |
| EBITDA | n/a | CN¥328M | CN¥185M | -CN¥206M | -CN¥236M |
| Net income | CN¥183M | CN¥237M | CN¥160M | -CN¥149M | -CN¥226M |
| Free cash flow | CN¥141M | CN¥531M | CN¥208M | -CN¥131M | -CN¥178M |
| Capital expenditure | CN¥170M | CN¥144M | CN¥230M | CN¥129M | CN¥150M |
| Total debt | CN¥36.4M | CN¥35.3M | CN¥74.9M | CN¥127M | CN¥57.4M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Beijing Aosaikang Pharmaceutical 002755.SZ | $1.60B | -31% | -13% | 12% | 57.4× | 12.8% |
| China Resources Double-Crane Pharmaceutical 600062.SS | $2.35B | -14% | -1% | 13% | 9.3× | -9.1% |
| Jiangsu Hengrui Pharmaceuticals 600276.SS | $45.7B | -13% | +6% | 27% | 33.4× | 13.4% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 002755.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -6.2% | -3.8% | 9th lowest of 21 |
| 6-month return | -31.3% | -7.7% | 4th lowest of 20 |
| Distance from 52-week high | -42.8% | -29.4% | 5th lowest of 21 |
| Revenue growth (TTM) | -12.8% | +6.8% | 6th lowest of 20 |
| Operating margin | 12.0% | 12.4% | 10th lowest of 20 |
| Forward P/E | 57.4× | 23.8× | most expensive of 15 |
| Growth the price implies (Req g, 7 yrs) | 12.8% | 6.0% | 7th most demanding of 16 |
| Growth delivered (Del g) | -14.0% | +6.8% | 2nd lowest of 16 |
| Hurdle (Req g minus delivered) | +26.8 pp | +2.0 pp | 3rd most demanding of 16 |
| ROIC minus cost of capital | +15.2 pp | +0.6 pp | 4th highest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Beijing Aosaikang Pharmaceutical 002755.SZ | China | $1.60B | -31% | -13% | 12% | 57.4× | 12.8% | -14.0% |
| Sino Biological 301047.SZ | China | $1.60B | +27% | +20% | 17% | 51.6× | 31.1% | -15.1% |
| Shanghai Shyndec Pharmaceutical 600420.SS | China | $1.59B | -14% | -13% | 6% | 12.6× | -6.6% | -5.6% |
| Jubilant Pharmova JUBLPHARMA.NS | India | $1.59B | -8% | +18% | 7% | 29.0× | n/a | n/a |
| Yantai Dongcheng Biochemicals 002675.SZ | China | $1.59B | 0% | -4% | 15% | 47.2× | 6.0% | -4.3% |
| Anupam Rasayan India ANURAS.NS | India | $1.61B | -3% | +24% | 16% | 49.9× | n/a | n/a |
| AstraZeneca Pharma India ASTRAZEN.NS | India | $1.62B | -30% | +30% | 10% | n/a | 42.4% | +23.0% |
| Yifan Pharmaceutical 002019.SZ | China | $1.57B | -19% | -5% | 8% | 25.6× | n/a | n/a |
| Tonghua Golden-Horse Pharmaceutical Industry 000766.SZ | China | $1.62B | -47% | -18% | 9% | n/a | 33.0% | +0.9% |
| Sarepta Therapeutics SRPT | United States | $1.56B | -15% | -19% | 0% | n/a | -6.8% | +32.4% |
| Consun Pharmaceutical 1681.HK | Hong Kong | $1.65B | +8% | +15% | 35% | 9.2× | -14.9% | +13.5% |
| Braveheart Bio BRVE | United States | $1.67B | n/a | n/a | n/a | n/a | n/a | n/a |
| Zhejiang CONBA Pharmaceutical 600572.SS | China | $1.52B | -4% | +4% | 9% | 16.0× | -6.1% | +1.9% |
| Zhejiang Wolwo Bio-Pharmaceutical 300357.SZ | China | $1.67B | -12% | +7% | 39% | 26.3× | 18.4% | +10.8% |
| JiangXi Tianxin Pharmaceutical 603235.SS | China | $1.52B | -9% | +16% | 24% | n/a | -4.9% | +0.2% |
| Indegene INDGN.NS | India | $1.69B | +28% | +36% | 12% | 29.5× | 31.4% | +29.4% |
| ABL Bio 298380.KS | South Korea | $1.51B | -71% | -53% | -201% | n/a | n/a | n/a |
| Mayinglong Pharmaceutical 600993.SS | China | $1.70B | +2% | +7% | 17% | 17.0× | -3.5% | +6.8% |
| Caplin Point Laboratories CAPLIPOINT.NS | India | $1.70B | +2% | +17% | 31% | 21.4× | 24.3% | +15.7% |
| ApicHope Pharmaceutical 300723.SZ | China | $1.70B | -36% | -28% | -50% | 22.0× | 11.3% | -11.0% |
| Faes Farma FAE.MC | Spain | $1.71B | +6% | +32% | 14% | 17.4× | 3.7% | +9.9% |